This company listing is no longer active
Destiny Pharma Past Earnings Performance
Past criteria checks 0/6
Destiny Pharma's earnings have been declining at an average annual rate of -4.9%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 51.3% per year.
Key information
-4.9%
Earnings growth rate
10.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 51.3% |
| Return on equity | -61.6% |
| Net Margin | -680.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Destiny Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -6 | 8 | 0 |
| 30 Sep 23 | 1 | -6 | 8 | 0 |
| 30 Jun 23 | 1 | -6 | 8 | 0 |
| 31 Mar 23 | 1 | -6 | 8 | 0 |
| 31 Dec 22 | 0 | -7 | 8 | 0 |
| 30 Sep 22 | 0 | -6 | 8 | 0 |
| 30 Jun 22 | 0 | -6 | 7 | 0 |
| 31 Mar 22 | 0 | -6 | 7 | 0 |
| 31 Dec 21 | 0 | -5 | 6 | 0 |
| 30 Sep 21 | 0 | -5 | 7 | 0 |
| 30 Jun 21 | 0 | -5 | 7 | 0 |
| 31 Mar 21 | 0 | -5 | 7 | 0 |
| 31 Dec 20 | 0 | -5 | 7 | 0 |
| 30 Sep 20 | 0 | -5 | 6 | 0 |
| 30 Jun 20 | 0 | -5 | 6 | 0 |
| 31 Mar 20 | 0 | -5 | 6 | 0 |
| 31 Dec 19 | 0 | -5 | 6 | 0 |
| 30 Sep 19 | 0 | -5 | 6 | 0 |
| 30 Jun 19 | 0 | -5 | 6 | 0 |
| 31 Mar 19 | 0 | -5 | 6 | 0 |
| 31 Dec 18 | 0 | -5 | 6 | 0 |
| 30 Sep 18 | 0 | -5 | 5 | 0 |
| 30 Jun 18 | 0 | -4 | 4 | 0 |
| 31 Mar 18 | 0 | -4 | 4 | 0 |
| 31 Dec 17 | 0 | -3 | 3 | 0 |
| 30 Sep 17 | 0 | -2 | 2 | 0 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -1 | 2 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 0 | -1 | 1 | 0 |
| 31 Dec 14 | 0 | -2 | 2 | 0 |
Quality Earnings: D89 is currently unprofitable.
Growing Profit Margin: D89 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: D89 is unprofitable, and losses have increased over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare D89's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: D89 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.8%).
Return on Equity
High ROE: D89 has a negative Return on Equity (-61.56%), as it is currently unprofitable.